FLFrank Leypoldt

Frank Leypoldt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frank Leypoldt has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autoimmune encephalitis: assay choice, pitfalls and predictive value

    by Justina Dargvainiene, Antje Torge, Kim Kristin Falk, Robert Markewitz, Klaus-Peter Wandinger, Ralf Junker, Frank Leypoldt

    Autoimmune encephalitides are rare, antibody-defined and treatable, and commercial assays have moved their diagnosis from specialised research laboratories into routine practice. Over 11 years in our laboratory the number of antibody analyses rose tenfold and the number of analytes per patient rose by 40 %. The proportion of patients with a positive result nevertheless remained near 6 %. The additional analytes identified no additional patients, and the already low pre-test probability per analyte has fallen further. Written for the laboratory, this review aims to provide practical guidance on raising the overall specificity and predictive value of the final report. It sets out what each assay format can and cannot do, which specimen to trust for which antibody, when a titre carries information, how to handle a result that only one technique supports, and which sample belongs in a referral laboratory. It also covers preanalytics, reader competence, external quality assessment and the regulatory framework for in-house assays. In general, the predictive value of a positive result is set not by the specificity of a single assay but by the whole pathway: serum and cerebrospinal fluid (CSF) read together, positives confirmed by a second technique, discordant findings referred rather than reported, and every result matched against the clinical syndrome. We propose graded levels of diagnostic certainty for common result constellations. In the future, reliable neuronal antibody diagnostics will depend less on new antigens than on disciplined reporting: internal training, consensus reading, quality control and dialogue with the requesting clinician.

  • Open Access

    CSF cytology: core principles, diagnostic pitfalls and emerging digital tools including artificial intelligence and telecytology

    by Sandra Nay, Franz Felix Konen, Franziska Bachhuber, Alexander Dressel, Deborah Erhart, Andreas Gerritzen, Catharina C. Gross, Andrea Harrer, Andrea Hinger, Piotr Lewczuk, et al.

    Cerebrospinal fluid cytology remains a cornerstone of diagnostic evaluation in infectious, autoimmune, haemorrhagic, and neoplastic disorders of the central nervous system despite advances in neuroimaging, molecular diagnostics, and digital technologies. This narrative review summarises established principles of cerebrospinal fluid cytology, highlights methodological limitations and diagnostic pitfalls, and integrates emerging developments, including automated cell counting, artificial intelligence, and telecytology. Pre-analytical factors are critical determinants of diagnostic accuracy. Delayed sample processing promotes pH-dependent autolysis and substantial cell loss, whereas rapid cytocentrifugation preserves cellular morphology and facilitates reliable assessment. Automated cell counters are increasingly implemented in routine laboratories and offer advantages in settings with limited technical staffing. However, current systems show limited precision in samples with low and slightly elevated cell counts and limited morphological evaluation. Manual chamber counting, particularly in the normal and low-cell-count range, remains the gold standard for quantitative CSF cell assessment, whereas expert microscopic examination remains the reference standard for qualitative cytomorphological assessment. Although the sensitivity of neuroimaging continues to improve, cerebrospinal fluid cytology retains a unique diagnostic role in the detection of infectious and neoplastic conditions and in the evaluation of subarachnoid haemorrhage. Cytological detection of erythrophages, siderophages, and haematoidin crystals can reveal haemorrhage and provide clues to its temporal stage. Overall, cerebrospinal fluid cytology remains a valuable diagnostic tool when integrated with clinical, laboratory, microbiological, immunological, and imaging findings. Careful recognition of common pitfalls is essential. We recommend rapid cerebrospinal fluid processing, routine preparation of cytospin-based stained slides with expert microscopic review, and the implementation of automated or digital methods only within clearly validated workflows.

  • Open Access

    Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network

    by Dominique Endres, Katharina von Zedtwitz, Ludger Tebartz van Elst, Katharina Domschke, Judith Weiser, Arnim J. Gaebler, Thomas Frodl, Elias Wagner, Iris Jäger, Alkomiet Hasan, et al.

    Psychiatric syndromes can be caused by underlying autoimmune encephalitis (AE). This represents a diagnostic challenge at the interface of psychiatry and neurology. While AE mostly manifests with a combined, complex neuropsychiatric syndrome, some patients with AE may (initially) present with predominant or isolated psychiatric symptoms. These cases can be difficult to classify, and diagnostic approaches vary considerably across clinical settings. This paper from the GErman NEtwork for Research on AuToimmune Encephalitis (GENERATE) provides interdisciplinary expert recommendations from psychiatry and neurology for the diagnostic evaluation of patients with suspected AE as the cause of psychiatric syndromes for psychiatric care settings. It integrates current scientific evidence with practical, empirical considerations from routine clinical care in different healthcare settings. The proposed diagnostic approach to detect psychiatric manifestations of AE emphasizes a rational, stepwise evaluation incorporating clinical assessment, magnetic resonance imaging, electroencephalography, blood testing, cerebrospinal fluid (CSF) analysis, and neuronal/glial antibody testing in serum and CSF. In diagnostically ambiguous individuals, [¹⁸F]fluorodeoxyglucose positron-emission-tomography and advanced antibody testing (e.g., live-cell-based assays) or neuroimaging techniques (e.g., volumetric analysis) may provide additional supportive information. Typical findings and limitations of diagnostic modalities are discussed to facilitate appropriate interpretation and to avoid under-recognition or overdiagnosis. Importantly, these recommendations do not aim to define new disease entities or diagnostic criteria, but rather to support a harmonized and pragmatic diagnostic approach to patients presenting with psychiatric syndromes suspected to be caused by underlying AE. Finally, key unresolved issues in this evolving field of immunopsychiatry are outlined, and promising research strategies are described.

  • Open Access

    Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis

    by Franz Felix Konen, Erda Bucak, Franziska Bachhuber, Justina Dargvainiene, Mar Guasp, Juliette Brenner, Anna Lena Streichert, Dominica Hudasch, Lina Marie Albers, Saskia Räuber, et al.

    Background and ObjectivesReliable biomarkers for autoimmune encephalitis (AE) are limited, and emerging CSF markers are not incorporated into current diagnostic criteria. Prognostic tools remain in...


  • Open Access

    Impaired consolidation of spatial memory during sleep in patients with leucine-rich glioma-inactivated 1-associated- limbic encephalitis

    by Julius Rave, Annika Hanert, Younes Adam Tabi, Yasmin Fiedler, Sarah Philippen, Oliver Granert, Frank Leypoldt, Jan Born, Andrea Burgalossi, Robby Schönfeld, et al.

    Sleep promotes the systems consolidation of hippocampus-dependent spatial memories by reprocessing of previously encoded hippocampal representations. Hippocampal reprocessing involves pattern separation and pattern completion as central hippocampal functions performed by the dentate gyrus (DG) and cornu ammonis region 3 (CA3) respectively. The leucine-rich, glioma inactivated 1 (LGI1)-associated limbic encephalitis (LE) is an autoimmune brain disorder particularly affecting the DG and CA3 regions thereby impairing hippocampal function. We studied 15 LGI1 patients (and matched healthy controls) to examine hippocampal contributions to the sleep-associated consolidation of spatial memory. Spatial memory was assessed using the Virtual Morris Water Maze (VWM) during learning before nocturnal sleep. Spatial retrieval of target locations (as indicated by dwell-time in target area) was tested in the next morning, with separate trials testing pattern separation and pattern completion functions, as well as place memory precision and reversal learning capabilities. LGI1-LE patients were able to learn and retrieve spatial locations, albeit to a lesser extent than controls. Recall of place memories was decreased in LGI1-LE patients in comparison with learning performance before sleep and with healthy controls, especially in trials assessing pattern separation. Moreover, at recall, LGI1 patients showed a less flexible adaptation to the reversal learning task, in comparison with the controls. Sleep quality, macro-sleep architecture and EEG slow oscillations (SOs) and spindles were comparable in both groups. However, in LGI1-LE patients, phase-amplitude coupling of SO-spindle events appeared diminished although the group difference did not remain significant after correction for multiple comparisons. In addition, a negative correlation between spindle density and retrieval of target locations was observed. MR-imaging confirmed smaller volumes of the hippocampus (HC) and its subfields (subiculum, CA1, CA3, DG) in the patients. Divergent structure–function relationships emerged between patients with LGI1-associated encephalitis and healthy controls: In patients, larger volumes of DG and CA3 were associated with weaker sleep-dependent consolidation but greater stability under cue deprivation. In controls, larger hippocampal, CA1, and subicular volumes correlated with better memory retrieval and reversal learning performance. Our results show an impaired sleep-associated consolidation of spatial memory in LGI1-LE patients highlighting the involvement of DG and CA3 areas in sleep-associated spatial memory formation and cognitive flexibility.


  • Autoimmunenzephalitis

    by M. Brokbals, M. Krämer, F. Leypoldt

  • Open Access

    Reduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic

    by Jonathan Wickel, Ha-Yeun Chung, Franz Felix Konen, Rosa Rössling, Annikki Bertolini, Andrea Kraft, Kai Siebenbrodt, Stefan Bittner, Aleksandra Juranek, Mosche Brokbals, et al.

    The aim of this study was to analyze changes in hospital incidence cases and disease severity of autoantibody-associated autoimmune encephalitis (AE) during the COVID-19 pandemic compared with the prepandemic period. A retrospective multicenter study analyzed data from 24 centers within the German Network for Research on Autoimmune Encephalitis (GENERATE). Patients with a new diagnosis of definite antibody-positive autoimmune encephalitis from 2017 to 2022 were included and divided into prepandemic (2017-2019) and pandemic (2020-2022) periods. Among 392 patients, 227 were diagnosed before and 165 during the pandemic (mean 9.5 vs 6.9 per site, p = 0.04). A reduction was observed in cases with antibodies to neuronal surface antigens (174 vs 122 cases; mean 7.3 vs 5.1 per site, p = 0.02), while cases with antibodies against intracellular antigens remained stable (p = 0.40). No differences were observed in disease severity, age, or sex distribution between periods. This study provides clinical data on antibody-positive AE before and during the COVID-19 pandemic. The findings do not support the hypothesis that SARS-CoV-2 infection triggers autoantibody-associated AE or increases disease severity.

  • Open Access

    T cells in antibody-associated CNS autoimmunity: a mechanistic approach across autoimmune encephalitis and paraneoplastic disorders

    by Frank Leypoldt, Alexander Scheffold, Carina Saggau

    Purpose of review: Autoimmune encephalitis (AE), paraneoplastic neurological syndromes (PNS), and glial antibody–mediated disorders (for example, AQP4-NMOSD) are traditionally classified based on the target antigens of their respective autoantibodies. However, recent insights from immunogenomics, single-cell sequencing, and neuropathology indicate that T cell programs substantially influence disease initiation, localization, and chronicity. This review highlights three emerging dimensions of T-cell involvement – circulating exhausted-like helper T-cell memory, intrathecal T–B cooperation, and parenchymal tissue-resident cytotoxicity – that offer new perspectives on clinical and pathological features across these disorders. Recent findings: In AQP4-NMOSD, circulating exhausted-like CD4 + T cells may constitute a durable autoreactive memory reservoir capable of re-initiating plasmablast responses. In LGI1- and CASPR2-associated encephalitis, systemic and intrathecal CD4 + differentiation appears to support systemic antibody maturation and local plasmablast expansion, with emerging hints of some accompanying CD8 + -mediated tissue injury. In contrast, in PNS and intracellular antigen–associated AE, CD8 + T cell-mediated cytotoxicity dominates and is characterized by parenchymal CD8 + tissue-resident memory (TRM) signatures. Summary: These T-cell dimensions may provide a useful framework for understanding clinical paradoxes – such as relapse despite B-cell depletion, persistent memory dysfunction in IgG4-AE, and therapeutic inefficacy in PNS – and suggest opportunities for therapeutic strategies targeting exhausted T-cell memory, intrathecal cooperation, or TRM stability.


  • Open Access

    [ 18 F ]Fluorodeprenyl‐ D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

    by Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, et al.

    Objective: To evaluate [ 18 F]fluorodeprenyl‐D2 ([ 18 F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods: [ 18 F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and static (30–60 min) acquisitions. Global astrogliosis was assessed by volumes of distribution (VT; 1‐tissue‐compartment model with carotid input) and standardized uptake values (SUV). Regional cerebellar and mesiotemporal (MT) uptake was normalized to global uptake (SUVr). PET measures were correlated with clinical phenotypes, MRI findings, and serum biomarkers (neurofilament light chain [sNfL], GAD65‐Ab titers, and glial fibrillary acidic protein [sGFAP]). Results: Clinical phenotypes included limbic encephalitis/temporal lobe epilepsy (LE/TLE; n = 17), stiff‐person syndrome ( n = 4), and cerebellar ataxia (CA; n = 4), with overlap in nine patients. Global [ 18 F]F‐DED uptake was higher in patients than controls. VT analysis showed increased cortical and MT uptake, while SUVr analysis demonstrated elevated MT uptake across the cohort. LE/TLE patients exhibited increased MT uptake, and CA patients showed higher cerebellar uptake. [ 18 F]F‐DED uptake did not correlate with sNfL or GAD65‐Ab titers, but sGFAP showed associations with cerebellar and white‐matter uptake. Regional uptake correlated with clinical severity in LE/TLE (MT lobe) and CA (cerebellar white matter). Interpretation: [ 18 F]F‐DED PET reveals region‐specific astrogliosis corresponding to clinical manifestations and disease severity in GAD65‐AIE, supporting its potential as a monitoring tool for disease activity.


  • Top Cited Papers
    Open Access

    Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks

    by Paulus S. Rommer, Wei Jiang, Jan P. Nolte, Takahisa Mikami, Jerome De Seze, Pedro Sánchez, Asaff Harel, Samir Alkabie, Kimihiko Kaneko, Philippe A. Bilodeau, et al.

    Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease mainly driven by aquaporin-4 antibodies (AQP4-IgG). During an attack, AQP4-IgG activates the complement system, leading to astrocyte destruction, inflammation, neuronal damage, and thus devastating and often irreversible neurologic deficits. Terminal complement inhibitors such as eculizumab and ravulizumab effectively prevent relapses, yet their therapeutic potential in stopping ongoing complement-mediated injury during acute attacks remains insufficiently explored. We conducted a multinational retrospective case series across NMOSD-specialized centers in 6 countries, analyzing 33 AQP4-IgG-positive patients (mean age: 48.1 years; 28 women) treated with component 5 (C5) inhibition during or shortly after acute relapse (mean 20.1 days from symptom onset; range 2-62). Eculizumab was used in 25 patients and ravulizumab in 8. Two additional patients were excluded because of delayed treatment initiation beyond 62 days. Lesion locations included myelitis (57.6%) and optic neuritis (30.3%). Expanded Disability Status Scale scores worsened from a pre-relapse median of 0 (interquartile range [IQR] 0-2) to a nadir of 6.5 (IQR 3.5-8), improving to 3.5 (IQR 3-6.5) at 1-3 months and 2.5 (IQR 2-6) at 6 months. All patients stabilized clinically; 20 continued C5 inhibition as attack-preventing therapy. Good, moderate, and poor/absent recovery were observed in 15, 11, and 7 patients, respectively. Earlier treatment was associated with better outcomes: treatment within 21 days yielded an odds ratio of 1.58 (95% CI 0.32-8.52) for good response. Plasma exchange was administered in 57.6% and was associated with higher overall response rates, but not with good response alone. These findings highlight the potential of complement inhibition as a treatment option for acute NMOSD attacks, particularly in patients with insufficient response to standard therapies. Given the absence of clinical worsening and the encouraging course observed in most of the patients, further investigation into the role of C5 inhibition in acute attack management is warranted. This retrospective case series provides Class IV evidence that the C5 complement inhibitors eculizumab or ravulizumab may improve disability in patients with NMOSD when given during or shortly after acute relapse.